Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence.

Inês Soares de PinhoPaulo LuzLucy AlvesRaquel Lopes-BrásVanessa PatelMiguel Esperança-MartinsLisa GonçalvesRitas FreitasDiana SimãoMaria Roldán GalnaresIsabel FernandesSilvia Artacho CriadoSalvador Gamez CasadoJose Baena CañadaIsabel M Saffie VegaJoão G CostaAna S FernandesRita Teixeira de SousaLuís Costa

Published in: Clinical drug investigation (2023)

This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.

Keyphrases

rectal cancer
lymph node
locally advanced
squamous cell carcinoma
early breast cancer
emergency department
metabolic syndrome
combination therapy
adverse drug
young adults